Vinay Prasad returns to US' FDA, resumes role overseeing vaccine, gene therapy, STAT News reports
ReutersAug 9, 2025 3:39 PM
Aug 9 (Reuters) - Vinay Prasad is returning to his role at the U.S. Food and Drug Administration to resume overseeing vaccine, gene therapy and blood product regulation, STAT News reported on Saturday.
"At the FDA's request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research," STAT News quoted Health and Human Services spokesperson Andrew Nixon as saying.
Prasad left the agency in July after just three months as director of the center.
Reuters could not immediately verify the report.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
BoE August Rate Decision Commentary: Where Next for the Pound?
TradingKey - On 7 August 2025, the Bank of England (BoE) lowered its benchmark interest rate from 4.25% to 4%, aligning with broad market expectations. Notably, the decision sparked significant division within the committee, requiring two rounds of voting to pass.TradingKey
Fri, Aug 8
U.S. GDP, PCE, and Fed Rate Decision Commentary: Will U.S. Stocks Continue to Rise?
TradingKey - On 30–31 July 2025, the United States released its latest GDP and PCE data, while the Federal Reserve announced its interest rate decision during the same period.TradingKey
Fri, Aug 1
Ethereum Price Prediction: Will ETH Extend the Rally? What’s the Future Trend?
Ethereum's impressive 2025 rally has been largely fueled by inflows from spot ETFs and a surge in institutional holdings, signaling growing confidence in its role as a core asset in the crypto market. However, to officially confirm the start of a new bull cycle, ETH must break above the critical $4,TradingKey
Wed, Jul 23
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.TradingKey
Wed, Jul 16
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
